Search

Author/Creator Saban, Revital

1. Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long‐term follow‐up of a multi‐center prospective study. Issue 1 (17th October 2019)

Authors:
Ofran, Yishai; Hayun, Michal; Leiba, Ronit; Zuckerman, Tsila; Horowitz, Netanel; Hoffman, Ron; Ringelstein, Shimrit; Lavi, Noa; Frisch, Avraham; Henig, Israel; Gatt, Moshe E.; Hellmann, Ilana; Arad, Ariela; Bulvik, Shlomo; Ram, Ron; Gino‐Moor, Sharon; Saban, Revital; Tvito, Ariella; Rowe, Jacob M...
Journal:
American journal of hematology
Issue:
Volume 95:Issue 1(2020:Jan.)
Page Start:
E3
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma. (2nd January 2023)

Authors:
Shamriz, Oded; Parnasa, Elchanan; Rubin, Limor; Talmon, Aviv; Ribak, Yaarit; Lebel, Eyal; Vainstein, Vladimir; Aumann, Shlomzion; Saban, Revital; Gatt, Moshe E.; Tal, Yuval
Journal:
European journal of haematology
Issue:
Volume 110:Number 4(2023)
Page Start:
407
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia. Issue 12 (17th November 2015)

Authors:
Ofran, Yishai; Leiba, Ronit; Ganzel, Chezi; Saban, Revital; Gatt, Moshe; Ram, Ron; Arad, Ariela; Bulvik, Shlomo; Hellmann, Ilana; Gino‐Moor, Sharon; Zuckerman, Tsila; Hoffman, Ron; Horowitz, Netanel; Lavi, Noa; Ringelstein, Shimrit; Henig, Israel; Hayun, Michal; Rowe, Jacob M.
Journal:
American journal of hematology
Issue:
Volume 90:Issue 12(2015:Dec.)
Page Start:
1159
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma. Issue 9 (29th July 2022)

Authors:
Lebel, Eyal; Goldschmidt, Neta; Siegal, Tali; Lossos, Alexander; Rosenberg, Shai; Makranz, Chen; Linetski, Eduard; Gatt, Moshe E.; Gural, Alexander; Saban, Revital; Lavie, David; Vainstein, Vladimir; Zimran, Eran; Avni, Batia; Grisaro, Sigal; Shaulov, Adir; Nachmias, Boaz
Journal:
Leukemia & lymphoma
Issue:
Volume 63:Issue 9(2022)
Page Start:
2102
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗